{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T08:11:29Z","timestamp":1781683889051,"version":"3.54.5"},"reference-count":30,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1111\/1469-0691.12521","type":"journal-article","created":{"date-parts":[[2013,12,26]],"date-time":"2013-12-26T12:19:46Z","timestamp":1388060386000},"page":"1297-1303","source":"Crossref","is-referenced-by-count":9,"title":["Immune activation throughout a boosted darunavir monotherapy simplification strategy"],"prefix":"10.1016","volume":"20","author":[{"given":"O.J.","family":"BenMarzouk-Hidalgo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Torres-Cornejo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Guti\u00e9rrez-Valencia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Ruiz-Valderas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Viciana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.F.","family":"L\u00f3pez-Cort\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Antonelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1111\/1469-0691.12521_bib1","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1097\/QAD.0b013e32834c4ac1","article-title":"Impact of CD8+ T\u2010cell activation on CD4+ T\u2010cell recovery and mortality in HIV\u2010infected Ugandans initiating antiretroviral therapy","volume":"25","author":"Hunt","year":"2011","journal-title":"AIDS"},{"key":"10.1111\/1469-0691.12521_bib2","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1093\/infdis\/jiq118","article-title":"Plasma levels of soluble CD14 independently predict mortality in HIV infection","volume":"203","author":"Sandler","year":"2011","journal-title":"J Infect Dis"},{"key":"10.1111\/1469-0691.12521_bib3","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1097\/QAI.0b013e3181926c28","article-title":"Premature aging of T cells is associated with faster HIV\u20101 disease progression","volume":"50","author":"Cao","year":"2009","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1111\/1469-0691.12521_bib4","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1097\/00126334-200204010-00004","article-title":"Predictive value of immunologic and virologic markers after long or short duration of HIV\u20101 infection","volume":"29","author":"Giorgi","year":"2002","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1111\/1469-0691.12521_bib5","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1097\/QAI.0b013e3182237e54","article-title":"Plasma sCD14 is a biomarker associated with impaired neurocognitive test performance in attention and learning domains in HIV infection","volume":"57","author":"Lyons","year":"2011","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1111\/1469-0691.12521_bib6","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1002\/path.2276","article-title":"Immune activation and inflammation in HIV\u20101 infection: causes and consequences","volume":"214","author":"Appay","year":"2008","journal-title":"J Pathol"},{"key":"10.1111\/1469-0691.12521_bib7","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1742-6405-10-3","article-title":"Boosted protease inhibitor monotherapy in HIV\u2010infected adults: outputs from a pan\u2010European expert panel meeting","volume":"10","author":"Arribas","year":"2013","journal-title":"AIDS Res Ther"},{"key":"10.1111\/1469-0691.12521_bib8","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1097\/QAD.0b013e32833dec20","article-title":"Efficacy of darunavir\/ritonavir maintenance monotherapy in patients with HIV\u20101 viral suppression: a randomized open\u2010label, noninferiority trial, MONOI\u2010ANRS 136","volume":"24","author":"Katlama","year":"2010","journal-title":"AIDS"},{"key":"10.1111\/1469-0691.12521_bib9","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1097\/01.qai.0000180077.59159.f4","article-title":"Lopinavir\/ritonavir as single\u2010drug therapy for maintenance of HIV\u20101 viral suppression: 48\u2010week results of a randomized, controlled, open\u2010label, proof\u2010of\u2010concept pilot clinical trial (OK study)","volume":"40","author":"Arribas","year":"2005","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1111\/1469-0691.12521_bib10","doi-asserted-by":"crossref","first-page":"F1","DOI":"10.1097\/QAD.0b013e3282f4243b","article-title":"Lopinavir\u2013ritonavir monotherapy versus lopinavir\u2013ritonavir and two nucleosides for maintenance therapy of HIV","volume":"22","author":"Pulido","year":"2008","journal-title":"AIDS"},{"key":"10.1111\/1469-0691.12521_bib11","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1093\/jac\/dkm198","article-title":"Lopinavir\/ritonavir monotherapy as a simplification strategy in routine clinical practice","volume":"60","author":"Molto","year":"2007","journal-title":"J Antimicrob Chemother"},{"key":"10.1111\/1469-0691.12521_bib12","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1093\/jac\/dkq327","article-title":"Lopinavir\/ritonavir monotherapy versus current treatment continuation for maintenance therapy of HIV\u20101 infection: the KALESOLO trial","volume":"65","author":"Meynard","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"10.1111\/1469-0691.12521_bib13","doi-asserted-by":"crossref","first-page":"e23726","DOI":"10.1371\/journal.pone.0023726","article-title":"Pilot, randomized study assessing safety, tolerability and efficacy of simplified LPV\/r maintenance therapy in HIV patients on the 1 PI\u2010based regimen","volume":"6","author":"Cahn","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1111\/1469-0691.12521_bib14","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1310\/hct1006-368","article-title":"Monotherapy with lopinavir\/ritonavir as maintenance after HIV\u20101 viral suppression: results of a 96\u2010week randomized, controlled, open\u2010label, pilot trial (KalMo study)","volume":"10","author":"Nunes","year":"2009","journal-title":"HIV Clin Trials"},{"key":"10.1111\/1469-0691.12521_bib15","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1086\/589622","article-title":"A 96\u2010week comparison of lopinavir\u2013ritonavir combination therapy followed by lopinavir\u2013ritonavir monotherapy versus efavirenz combination therapy","volume":"198","author":"Cameron","year":"2008","journal-title":"J Infect Dis"},{"key":"10.1111\/1469-0691.12521_bib16","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1111\/j.1468-1293.2012.00989.x","article-title":"The MONET trial: week 144 analysis of the efficacy of darunavir\/ritonavir (DRV\/r) monotherapy versus DRV\/r plus two nucleoside reverse transcriptase inhibitors, for patients with viral load <50 HIV\u20101 RNA copies\/ml at baseline","volume":"13","author":"Arribas","year":"2012","journal-title":"HIV Med"},{"key":"10.1111\/1469-0691.12521_bib17","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1093\/jac\/dkr504","article-title":"Long\u2010term efficacy of darunavir\/ritonavir monotherapy in patients with HIV\u20101 viral suppression: week 96 results from the MONOI ANRS 136 study","volume":"67","author":"Valantin","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"10.1111\/1469-0691.12521_bib18","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1093\/infdis\/jir518","article-title":"Factors associated with virological failure in HIV\u20101\u2010infected patients receiving darunavir\/ritonavir monotherapy","volume":"204","author":"Lambert\u2010Niclot","year":"2011","journal-title":"J Infect Dis"},{"key":"10.1111\/1469-0691.12521_bib19","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1097\/QCO.0b013e32834ef5d9","article-title":"Low\u2010level viraemia on HAART: significance and management","volume":"25","author":"Doyle","year":"2012","journal-title":"Curr Opin Infect Dis"},{"key":"10.1111\/1469-0691.12521_bib20","first-page":"156","article-title":"2011 update of the drug resistance mutations in HIV\u20101","volume":"19","author":"Johnson","year":"2011","journal-title":"Top Antivir Med"},{"key":"10.1111\/1469-0691.12521_bib21","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1086\/427340","article-title":"Low\u2010level viremia and proviral DNA impede immune reconstitution in HIV\u20101\u2010infected patients receiving highly active antiretroviral therapy","volume":"191","author":"Ostrowski","year":"2005","journal-title":"J Infect Dis"},{"key":"10.1111\/1469-0691.12521_bib22","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1002\/cyto.a.20643","article-title":"Phenotype and function of human T lymphocyte subsets: consensus and issues","volume":"73","author":"Appay","year":"2008","journal-title":"Cytometry A"},{"key":"10.1111\/1469-0691.12521_bib23","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1177\/135965350200700404","article-title":"Transient rebounds of low\u2010level viraemia among HIV\u2010infected patients under HAART are not associated with virological or immunological failure","volume":"7","author":"Mira","year":"2002","journal-title":"Antivir Ther"},{"key":"10.1111\/1469-0691.12521_bib24","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1097\/00002030-200208160-00008","article-title":"Consecutive rebounds in plasma viral load are associated with virological failure at 52 weeks among HIV\u2010infected patients","volume":"16","author":"Raboud","year":"2002","journal-title":"AIDS"},{"key":"10.1111\/1469-0691.12521_bib25","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1097\/00002030-200210180-00008","article-title":"Prevalence and clinical correlates of HIV viremia (\u2018blips\u2019) in patients with previous suppression below the limits of quantification","volume":"16","author":"Sklar","year":"2002","journal-title":"AIDS"},{"key":"10.1111\/1469-0691.12521_bib26","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1097\/00002030-200404300-00005","article-title":"Immunologic and virologic evolution during periods of intermittent and persistent low\u2010level viremia","volume":"18","author":"Karlsson","year":"2004","journal-title":"AIDS"},{"key":"10.1111\/1469-0691.12521_bib27","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1097\/QAI.0b013e3182895af4","article-title":"CD8+T\u2010cell activation in HIV\u20101\u2010infected patients experiencing transient low\u2010level viremia during antiretroviral therapy","volume":"63","author":"Taiwo","year":"2013","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1111\/1469-0691.12521_bib28","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1016\/S0140-6736(05)60396-0","article-title":"Expression of CD38 on CD8 T cells predicts maintenance of high viraemia in HAART\u2010treated HIV\u20101\u2010infected children. Highly active antiretroviral therapy","volume":"352","author":"Vigano","year":"1998","journal-title":"Lancet"},{"key":"10.1111\/1469-0691.12521_bib29","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1097\/00042560-199710010-00003","volume":"16","author":"Liu","year":"1997","journal-title":"J Acquir Immune Defic Syndr Hum Retrovirol"},{"key":"10.1111\/1469-0691.12521_bib30","first-page":"904","article-title":"Elevated levels of CD38+ CD8+ T cells in HIV infection add to the prognostic value of low CD4+ T cell levels: results of 6 years of follow\u2010up. The Los Angeles Center, Multicenter AIDS Cohort Study","volume":"6","author":"Giorgi","year":"1993","journal-title":"J Acquir Immune Defic Syndr"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X15600301?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X15600301?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,7,9]],"date-time":"2023-07-09T08:50:15Z","timestamp":1688892615000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X15600301"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12]]},"references-count":30,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["S1198743X15600301"],"URL":"https:\/\/doi.org\/10.1111\/1469-0691.12521","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2014,12]]}}}